Studies related to Quality of Life and Saw Palmetto

Improving BPH Symptoms And Sexual Dysfunctions With A Saw Palmetto Preparation? Results From A Pilot Trial

Effect Increase
Values Urolife BPH QoL-9 total improved from 162.7  to 105.0 after 8 weeks
Trial Design Non-controlled trial
Trial Length 1-6 months
Number of Subjects 82
Gender Male
Age Range 30-44, 45-64, 65+
Notes for this study:
82 men received 320 saw palmetto extract daily for 8 weeks. International Prostate Symptom Score (IPSS) decreased from 14.4 ± 4.7 to 6.9 ± 5.2 over this time period, SDys score measured using the brief Sexual Function Inventory improved from 22.4  to 31.4, and Urolife BPH QoL-9 score improved from 137.3 to 195.0 over this time period, with all these results being statistically significant. This was an open-label, uncontrolled trial, however.
Funding issues for this study:
The specific brand of saw palmetto used, Prostasan, was manufactured by the funder of the study, and the lead author is an employee of the manufacturer.

Effect Of Increasing Doses Of Saw Palmetto Extract On Lower Urinary Tract Symptoms: A Randomized Trial

Effect None
Values The AUASI QoL index dropped from 0.34 points in the saw palmetto group and 0.49 points in the placebo group, with an insignificant difference between groups
Trial Design Randomized trial
Trial Length 6+ Months
Number of Subjects 369
Gender Male
Age Range 45-64, 65+
Notes for this study:
Men over 45 years of age with AUA symptom score between 8 and 24 were randomly assigned to placebo or escalating doses of saw palmetto, which consisted of 320mg for first 24 weeks, 640mg for next 24 weeks, and 960mg for the final 24 weeks, for a total of 72 weeks. Serum PSA levels were measured with no difference between the saw palmetto group and placebo at any of the time points. Mean AUASI score decreased significantly over the course of the study in both placebo and saw palmetto groups (14.42 to 12.22 for saw palmetto, 14.69 to 11.70 for placebo), with no statistically significant difference between them. Many additional secondary measure were taken, including AUASI QoL, objective and subjective urinary flow measures, and sexual function measures. All were not significantly different between placebo and saw palmetto.
Funding issues for this study:
Manufacturer donated saw palmetto and matching placebo, but had no role in funding or design otherwise